Agreed. Although the world is getting smaller and smaller.
We can only rule out so many huge countries and still have a viable path to real revenue.
Not only that, but Europe in general does not spend a lot on drugs. According to Amarin, the U.S. has a population of 335M people, and spends >$600B annually on pharma drugs. Europe has a population of 600M, and spends only $200B. So the opportunity in Europe is MUCH smaller than the U.S. (smaller by like 2/3).
My concern is that we have no path to significant revenue for several more years, even in Europe.
Market Data 
Markets 
AI
